| Business Summary | | Rigel
Pharmaceuticals,
Inc.
is
a
drug
discovery
company
that
utilizes
combinatorial
biology
to
discover
novel
drug
targets
and
drug
candidates
that
regulate
these
targets.
In
four
years
of
research
using
its
technology,
the
Company
has
initiated
12
programs
through
which
it
has
identified
several
new
drug
targets
in
11
of
its
programs,
and
has
generated
compounds
in
six
programs.
Rigel
has
programs
in
asthma/allergy,
autoimmunity,
transplant
rejection,
rheumatoid
arthritis,
inflammatory
bowel
disease,
chronic
bronchitis,
cancerous
tumor
growth
and
hepatitis
C.
The
Company's
technologies
are
designed
to
identify
protein
targets
for
compound
screening
and
validate
the
role
of
those
targets
in
the
disease
process. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Rigel
Pharmaceuticals,
Inc.
is
engaged
in
the
discovery
and
development
of
a
broad
range
of
new
small
molecule
drug
candidates.
The
company
uses
post-genomics
combinatorial
biology
technology
to
discover
novel
drug
targets.
For
the
six
months
ended
6/30/01,
revenues
fell
7%
to
$6.3
million.
Net
loss
applicable
to
Common
fell
49%
to
$11.5
million.
Results
reflect
the
absence
of
payments
received
from
a
partner,
offset
by
the
absence
of
preferred
dividends. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| James Gower, 52 Pres,
CEO, Director | $268K | -- | Brian Cunningham, 57 COO,
Chief Financial Officer, Sr. VP, Sec. | 258K | $2.0M | Donald Payan, M.D., 52 Exec.
VP and CSO | 247K | -- | James Welch, 43 VP
of Fin. and Admin., Assistant Sec. | 154K | 161K | Raul Rodriguez, 40 VP-Bus.
Devel. | 177K | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|